AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...

REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Two ...

We have a proven target, VEGF, and proven treatments for decades ... the risk that the Company and the FDA may not agree on the registrational pathway for AXPAXLI for NPDR or any other indication; ...